GlassScriptPhysician profile
Ryan Atwood
NPI 1023656782
$1,444.49
in general payments reported to CMS, 2019-2025
20 companies · $14.18 in 2025
The $14.18 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $414 · 2023: $398 · 2024: $618 · 2025: $14.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.71 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $192.50 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $186.49 | 2022-2024 | |
| Mylan Specialty L.P. | $98.88 | 2022-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.60 | 2023-2024 | Caplyta |
| Lilly USA, LLC | $91.12 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $90.53 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $78.81 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.48 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $57.47 | 2022-2024 | Invega Sustenna, Spravato |
| Pfizer INC. | $54.95 | 2022-2023 | |
| Glaxosmithkline, LLC. | $42.02 | 2023-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $27.37 | 2024 | Rexulti |
| Dexcom, INC. | $25.87 | 2022 | |
| Vanda Pharmaceuticals INC. | $25.65 | 2024 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $20.37 | 2023 | Aristada, Lybalvi |
| Lucid Diagnostics INC. | $15.18 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.15 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.31 | 2022 | |
| Merck Sharp & Dohme LLC | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Atwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.